Xenon Pharmaceuticals (XENE) Revenue (2013 - 2025)

Xenon Pharmaceuticals (XENE) posted quarterly Revenue of $7.5 million for Q1 2025, up 5581.82% quarter-over-quarter from $132000.0 in Q3 2022.

Xenon Pharmaceuticals (XENE) Revenue (2013 - 2025) Analysis & Trends

Xenon Pharmaceuticals (XENE) has reported Revenue for 10 consecutive years, with $7.5 million the latest figure, recorded in Q1 2025.

In Q1 2025, Revenue changed N/A year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $7.5 million (changed N/A YoY), while the FY2025 annual figure was $7.5 million, changed N/A from the prior year.
Revenue rose to $7.5 million in Q1 2025 per XENE's latest filing, from $132000.0 in the prior quarter.
Across five years, Revenue topped out at $8.8 million in Q1 2022 and bottomed at $132000.0 in Q3 2022.
Historically, Revenue has averaged $4.4 million across 3 years, with a median of $4.0 million in 2021.
On a YoY basis, Revenue climbed as much as 101.15% in 2022 and fell as far as 98.38% in 2022.
Xenon Pharmaceuticals' Revenue stood at $3.7 million in 2021, then tumbled by 96.47% to $132000.0 in 2022, then soared by 5581.82% to $7.5 million in 2025.
Business Quant data shows XENE's Revenue at $7.5 million in Q1 2025, $132000.0 in Q3 2022, and $536000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Xenon Pharmaceuticals	6.03 Bn	6.03 Bn	-	-

Download Data